Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

Summary

This study recruits patients with metastatic breast cancer who have progressed on their current regimen of dual anti-HER2 therapy. This study evaluates whether or not the addition of simvastatin to the dual anti-HER2 therapy regimen helps make the tumor respond to the anti-HER2 therapy again. All participants will receive simvastatin in combination with their current anti-HER2 therapy regimen.

Timeline

Start

2020-03-04

Primary completion

2028-12

Completion

2030-12

Drugs

Indications